Abstract 2360
Background
Extranodal marginal zone lymphoma is a type of low-grade B-cell lymphoma and may be classified as mucosal-associated lymphoid tissue (MALT) lymphoma. MALT lymphoma is most common in stomach in Korea. The etiologic factors are inflammation caused by chronic infection, autoimmune disease and genetic variation. Identifying various somatic mutations is an essential process in precision medicine, where high throughput sequencing is used to accurately detect genetic changes. Nucleotide sequencing techniques are basically based on the Sanger method, but recently second generation or next generation sequencing (NGS) that can sequence millions or billions of DNA strands simultaneously in parallel unlike the sanger sequencing is rapidly spreading.
Methods
One gastric MALT lymphoma and four small intestine MLAT lymphomas were selected and studied using tissue samples embedded in their paraffin. DNA was extracted from tissue samples and quality control was performed. NGS was performed using HemaSCANTM, a custom panel for 426 genes including essential genes for blood cancer.
Results
The results of NGS revealed the following genomic variants; single nucleotide variations (SNVs), insertions and deletions (InDels) and copy number variations (CNVs). And these genomic variants are reported as annotated, known, and novel variants. Of the annotated variant, ERBB2 gene amplification was confirmed in one patient. Of the known and novel variants, SNV of SETBP6, RUNX1 and KEAP1 gene, InDel of MKI67 gene, CNV of ZNF703 and NOTCH1 gene were confirmed in two or more patients. And InDel with frameshift in BCL10, DDX3X, FOXO3 and MUC2 genes was identified in one patient.
Conclusions
Since there are few NGS studies on MALT lymphoma, the various mutations identified in this study cannot be said to be “inactionable”. More studies are needed to determine the association of various genetic mutations with the development of MALT lymphoma.
Clinical trial identification
Editorial acknowledgement
Seok Jae Huh1, Sung Yong Oh1, Suee Lee1, Ji Hyun Lee1, Sung Hyun Kim1, Min Kyung Park2, and Hyo-Jin Kim1 1Department of Internal Medicine, Dong-A University Hospital, Busan, Republic of Korea, 2Department of Pathology, Dong-A University College of Medicine, Busan, Republic of Korea.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2023 - Patients with brain metastases treated with afatinib in clinical practice – results from the prospective non-interventional study GIDEON
Presenter: Eckart Laack
Session: Poster Display session 1
Resources:
Abstract
1613 - Lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed continuously in combination with osimertinib for EGFRmut non-small cell lung cancer: initial Phase 1b results
Presenter: David Berz
Session: Poster Display session 1
Resources:
Abstract
2853 - Real-world implementation of sequential targeted therapies for EGFR-mutated NSCLC
Presenter: Petros Christopoulos
Session: Poster Display session 1
Resources:
Abstract
1974 - A Phase II Open-Label, Multicentre Study to Assess the Anti-tumour Activity of Afatinib in Patients with Activating Epidermal Growth Factor Receptor mutation (EGFRm) from Circulating Tumor DNA (CtDNA)
Presenter: Young-Chul Kim
Session: Poster Display session 1
Resources:
Abstract
3370 - Influence of cow’s milk on the absorption and exposure of erlotinib in NSCLC patients
Presenter: Geerten Veerman
Session: Poster Display session 1
Resources:
Abstract
5900 - PTEN loss as Predictor of Tumor Heterogeneity (TH) and Poor Prognosis in EGFR-mutant Advanced Non-Small Cell Lung Cancer (ANSCLC) Patients (pts) Receiving Tyrosine-Kinase Inhibitors (TKIs).
Presenter: Miriam Ferrara
Session: Poster Display session 1
Resources:
Abstract
1302 - Safety of lorlatinib in subgroups of patients from a phase 1/2 trial
Presenter: Enriqueta Felip
Session: Poster Display session 1
Resources:
Abstract
1497 - Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK+ NSCLC in the phase 2 ALTA trial
Presenter: Dae Ho Lee
Session: Poster Display session 1
Resources:
Abstract
2349 - The safety assessment of crizotinib and alectinib from real world data of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L).
Presenter: Kei Kunimasa
Session: Poster Display session 1
Resources:
Abstract
1120 - Brigatinib in ALK TKI-pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC): the Use Via Expanded Access to Brigatinib (UVEA-Brig) study
Presenter: Silvia Novello
Session: Poster Display session 1
Resources:
Abstract